Induction of type 1 interferon receptor by zinc in U937 cells

Cytokine

Volumn 46, Issue 3, 2009, Pages 346-350

  Nagamine, Takeaki ^a   Nakajima, Kastuyuki ^a   Takada, Hisashi ^a   Sekine, Yoshitaka ^a   Suzuki, Kazuhiro ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

2 5 Oligoadenylate synthetase; Interferon receptor; Polaprezinc; U937 cells; Zinc chloride

Indexed keywords

ALPHA INTERFERON; IFNRA2 PROTEIN; INTERFERON RECEPTOR; MESSENGER RNA; POLAPREZINC; POLYCLONAL ANTIBODY; RECEPTOR PROTEIN; UNCLASSIFIED DRUG; ZINC CHLORIDE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN U937; CONTROLLED STUDY; FLOW CYTOMETRY; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

2',5'-OLIGOADENYLATE SYNTHETASE; ANTI-ULCER AGENTS; CARNOSINE; CHLORIDES; HUMANS; INTERFERON-ALPHA; ORGANOMETALLIC COMPOUNDS; RECEPTOR, INTERFERON ALPHA-BETA; U937 CELLS; ZINC COMPOUNDS;

EID: 67349120225     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.03.005     Document Type: Article

References (33)

1. Pestka S., Krause C.D., and Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202 (2004) 8-32
2. Platanias L.C. Mechanisms of type-I and type-II interferon-mediated signaling. Nat ReV Immunol 5 (2005) 375-386
3. García-Sastre A., and Biron C.A. Type 1 interferons and the virus-host relationship: a lesson in détente. Science 312 (2006) 879-882
4. Kirkwood J.M., Bender C., Agarwala S., Tarhini A., Shipe-Spotloe J., Smelko B., et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 20 (2002) 3703-3718
5. Novick D., Cohen B., and Rubinstein M. The human interferon alpha/beta receptor: characterization and molecular cloning. Cell 77 (1994) 391-400
6. Roisman L.C., Jaitin D.A., Baker D.P., and Schreiber G. Mutational analysis of the IFNAR1 binding site on IFNalpha2 reveals the architecture of a weak ligand-receptor binding-site. J Mol Biol 353 (2005) 271-281
7. Lankin P., Gavutis M., Petres I., van der Heyden J., Uze G., and Pichler J. Functional cartography of the ectodomain of the type 1 interferon receptor subunit ifnar1. J Mol Biol 350 (2005) 476-488
8. de Weerd N.A., Samarajiwa S.A., and Hertzog P.J. Type 1 interferon receptors: biochemistry and biological functions. J Biol Chem 282 (2007) 20053-20057
9. Fukuda R., Ishimura N., Kushiyama Y., Moriyama N., Ishihara S., Nagasawa S., et al. Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver. J Hepatol 26 (1997) 455-461
10. Mathai J., Shimoda K., Banner B.F., Mori M., Bonkovsky H.L., and Barnard G.F. IFN-a receptor mRNA expression in a United States sample with predominantly genotype 1a/I chronic hepatitis C liver biopsies correlates with response to IFN therapy. J Interf Cytok Res 19 (1999) 1011-1018
11. Yatsuhashi H., Fujino T., Matsumoto T., Inoue O., Koga M., and Yano M. Immunohistochemical analysis of hepatic interferon alpha-beta receptor level: relationship between receptor expression and response to interferon therapy in patients with chronic hepatitis C. J Hepatol 30 (1999) 995-1003
12. Mizukoshi E., Kaneko S., Yanagi M., Ohno H., Kaji K., Terasaki S., et al. Expression of interferon alpha/beta receptor in the liver of chronic hepatitis C patients. J Med Virol 56 (1998) 217-223
13. Prasad A.S. Zinc in human health: an update. J Trace Elem Exp Med 11 (1998) 63-87
14. Andreini C., Banci L., Bertini L., and Rosato A. Counting the zinc-proteins encoded in the human genome. J Proteome Res 5 (2006) 196-201
15. Shankar A.H., and Prasad A.S. Zinc and immune function: the biological basis of altered resistance to infection. Am J Clin Nutr 68 (1998) 447S-463S
16. Yamasaki S., Sakata-Sogawa K., Hasegawa A., Suzuki T., Kabu K., Sato F., et al. Zinc is a novel intracellular second messenger. J Cell Biol 177 (2007) 647-657
17. Bao B., Prasad A.S., Beck F.W.J., and Godmere M. Zinc modulates mRNA levels of cytokines. Am J Physiol Endocrinol Metab 285 (2003) 1095-1102
18. Nagamine T., Takagi H., Takayama H., Kojima A., Kakizaki S., Mori M., et al. Preliminary study of combination therapy with interferon-α and zinc in chronic hepatitis C patients with genotype 1b. Biol Trace Elem Res 75 (2000) 53-63
19. Takagi H., Nagamine T., Abe T., Takayama H., Sato K., Otsuka T., et al. Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C. J Viral Hepat 8 (2001) 367-371
20. Geist F.C., Bateman J.A., and Hayden F.G. In vitro activity of zinc salts against human rhino viruses. Antimicrob Agents Chemother 31 (1987) 622-624
21. Berg K., Bolt G., Andersen H., and Owen T. Zinc potentiates the antiviral action of human IFN-α. J Interf Cytok Res 21 (2001) 471-474
22. Tochizawa S., Akamatsu S., Sugiyama Y., Muraguchi M., Ohmoto Y., Ono Y., et al. A flow cytometric method for determination of the interferon receptor IFNAR2 subunit in peripheral blood leukocyte subsets. J Pharmacol Toxicol Methods 50 (2004) 59-66
23. Suzuki K., Koike H., Matsui H., Ono Y., Hasumi M., Nakazato H., et al. Genistein, a soy isoflavone, induces glutathion peroxidase in the human prostate cancer cell lines LNCAP and PC-3. Int J Cancer 99 (2002) 846-852
24. Oie S., Ono M., Yano H., Maruyama Y., Terada T., Yamada Y., et al. The up-regulation of type 1 interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliferative effect by 5-fluorouracil and interferon-α. Int J Oncol 29 (2006) 1469-1478
25. Ota H., Nagano H., Sakon M., Eguchi H., Kondo M., Yamamoto T., et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 93 (2005) 557-564
26. Hamamoto S., Fukuda R., Ishimura N., Kumi M.A.K., Kazumori H., Uchida Y., et al. 9-Cis retinoic acid enhances the antiviral effect of interferon on hepatitis C virus replication through increased exspression of type 1 interferon receptor. J Lab Clin Med 141 (2003) 58-66
27. Sen G.C., and Ransohoff R.M. Interferon induced antiviral actions and their regulation. Adv Virus Res 42 (1993) 57-102
28. Stark G.R., Kern I.M., Williams B.R., Silverman R.H., and Schreiber R.D. How cells respond to interferons. Annu Rev Biochem 67 (1998) 227-264
29. Ueki S., Seiki M., Yoneta T., Omata T., Hori Y., Ishikawa M., et al. Effect of Z-103 on compound 48/80-induced gastric lesions in rats. Scand J Gastroenterol 24 (1987) 202-205
30. Shimada T., Watanabe N., Ohtsuka Y., Endoh M., Kojima K., Hiraishi H., et al. Polaprezinc down-regulates proinflammatory cytokine-induced nuclear factor-kappaB activation and interleukin-8 expression in gastric epithelial cells. J Pharmacol Exp Ther 291 (1999) 345-352
31. Tanaka S., Akaishi E., Hosaka K., Okamura S., and Kurohara Y. Zinc ions suppress mitogen-activated interleukin-2 production in Jurkat cells. Biochem Biophys Res Commun 335 (2005) 162-167
32. Bao B., Prasad A., Beck F.W.J., Suneja A., and Sarkar F. Toxic effect of zinc on NF-kappa B, IL-2, IL-2 receptor alpha, and TNF-alpha in HuT-78 (Th0) cells. Toxicol Lett 166 (2006) 222-228
33. Prasad A.S., Bao B., Beck F.W.J., and Sarkar F.H. Zinc enhances the expression of interleukin-2 and interleukin-2 receptors in HUT-78 cells by way of NF-B activation. J Lab Clin Med 140 (2002) 272-289